Insulin secretion from the pancreatic b-cell (referred to as b-cell hereafter) plays a central role in glucose homeostasis. Impaired insulin secretion is a major factor contributing to the development of diabetes and, therefore, is an important target for treatment of the disease. Cyclic adenosine monophosphate is a key second messenger in b-cells that amplifies insulin secretion. Incretins released by the gut potentiate insulin secretion through cyclic adenosine monophosphate signaling in b-cells, which is the basis for the incretin-based diabetes therapies now being used worldwide. Despite its importance, the interaction between glucose metabolism and incretin/cyclic adenosine monophosphate signaling in b-cells has long been unknown. A recent study showed that cytosolic glutamate produced by glucose metabolism in b-cells is a key signal in incretin-induced insulin secretion. Here we review the physiological and pathophysiological roles of b-cell glutamate signaling in incretin-induced insulin secretion.
INTRODUCTION
Insulin secretion from pancreatic b-cells is critical for the maintenance of glucose homeostasis, and its impairment is associated closely with the pathogenesis and pathophysiology of diabetes. Mechanisms of insulin secretion have been investigated extensively over several decades. In the 1980s, the major intracellular signals in insulin secretion were identified by physiological, pharmacological and biochemical methods. These signals include Ca 2+ , adenosine triphosphate (ATP), cyclic adenosine monophosphate (cAMP) and phospholipid-derived molecules, such as diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP 3 ) [1] [2] [3] . Glucose is physiologically the most important fuel of insulin secretion (glucose-induced insulin secretion [GIIS] ).
Metabolic coupling factors (MCFs) in fuel-induced insulin secretion (FIIS) have been reviewed elegantly by a recent paper 4 . Regulatory MCFs, such as citrate, malonyl-coenzyme A (CoA), glutamate and adenine nucleotides, modulate metabolic networks involved in FIIS, whereas the effectory MCFs, such as ATP, cAMP and nicotinamide adenine dinucleotide phosphate, are directly involved in the triggering and amplification of insulin secretion. There are also interactions between glucose and free fatty acid in b-cells. GIIS is thought to be associated with inhibition of free fatty acid oxidation and increased lipid synthesis in b-cells. Malonyl-CoA is known to be a key metabolite that lies at the crossroad of glucose metabolism and lipid metabolism, and is proposed to be an MCF for GIIS.
Amplification of GIIS by neuronal and hormonal inputs is also important for normal regulation of insulin secretion 5 . For example, acetylcholine, a neurotransmitter, stimulates insulin secretion through activation of muscarinic acetylcholine receptor in b-cells 6 . Incretins, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are secreted from the enteroendocrine cells in response to meal ingestion, potentiate insulin secretion in a glucosedependent manner through cAMP signaling 7 . However, how glucose metabolism and cAMP signaling interact with each other, and why incretin-induced insulin secretion is glucosedependent was not known. We recently found that cytosolic glutamate produced through the malate-aspartate (MA) shuttle in glucose metabolism in b-cells is a key cell signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion. In the present review, we discuss the physiological and pathophysiological roles of glutamate signaling in b-cells.
GLUCOSE-INDUCED INSULIN SECRETION AND ITS MODULATION BY HORMONAL AND NEURONAL INPUTS
GIIS involves two pathways, the triggering pathway and the metabolic amplifying pathway, and is modulated by various hormonal and neuronal inputs. ]i) triggers exocytosis of insulin granules 8 .
Metabolic amplifying pathway
It is known that in addition to ATP, various metabolic signals generated by glucose metabolism amplify insulin secretion. This pathway is called the "metabolic amplifying pathway." Although this pathway is not fully understood, augmentation of the effect of Ca 2+ on insulin secretion is thought to be involved 8 . A recent study suggested that three pyruvate cycling pathwaysthe pyruvate-malate shuttle, the pyruvate-citrate shuttle and the pyruvate-isocitrate shuttle -might be associated with the metabolic amplifying pathway 9 .
Modulation of insulin secretion by hormones and neurotransmitters
The actions of hormones and neurotransmitters in insulin secretion are mediated by their specific receptors, most of which are guanine-nucleotide-binding regulatory protein (G protein)-coupled receptors (GPCRs) 10 . GPCRs include Gs-, Gq/11-and Gi/o-protein-coupled receptors. They principally mediate two signaling pathways: the cAMP signaling pathway and the phosphatidylinositol signaling pathway. Ligand binding to GPCR causes its conformational change and activates G protein.
Both Gs protein signaling and Gq/11-protein signaling mediate amplification of GIIS. The incretins GLP-1 and GIP are known to potentiate insulin secretion through activation of Gs protein signaling followed by cAMP signaling pathways, which include the protein kinase A-dependent pathway and the Epac2A (also called cAMP-GEFII)-dependent pathway [11] [12] [13] . Acetylcholine amplifies insulin secretion through Gq/11-protein signaling by activation of phospholipase C-b, which produces IP 3 and DAG. IP 3 triggers Ca 2+ release from the endoplasmic reticulum, whereas DAG activates protein kinase C 14 . Gi/o-protein signaling mediates an inhibitory effect on GIIS, and is known to regulate K + and Ca 2+ channels directly and indirectly through suppression of cAMP production 10 . Somatostatin, noradrenaline and ghrelin inhibit insulin secretion through activation of Gi-protein signaling.
INCRETIN EFFECTS ON INSULIN SECRETION
It is well known that oral glucose load produces a much greater insulin secretion than intravenous injection of glucose, which is now recognized as the "incretin effect." Incretins, such as GIP and GLP-1, are gut hormones released from the gut in response to ingestion of glucose or nutrients 7 . GIP, a 42 amino acid hormone, is secreted from K cells of the upper part of the intestine; GLP-1, a 31 amino acid hormone, is secreted from L cells of the lower part of the intestine. GLP-1 and GIP potentiate insulin secretion through cAMP signaling in a glucose-dependent manner. It was found by perfusion of mouse pancreas that when the glucose concentration is increased in a stepwise manner from 2.8 to 12.5 mmol/L in the absence of cAMP-increasing agents (i.e., 8-Br-cAMP or GLP-1), no insulin secretion is induced, but the presence of the agents resulted in dramatic induction of insulin secretion 15 . Similar results also were found in Kir6.2 knockout mice, in which almost no GIIS was detected. These findings show that incretin/cAMP signaling is critical for the induction of glucose responsiveness in insulin secretion, as well as the potentiation of GIIS 5 . We found by total internal reflection fluorescence microscopy analysis that the cAMP analog 8-Br-cAMP enhanced the frequency of fusion events of insulin granules to the plasma membrane in the presence of glucose (but not by itself) in both the first phase and the second phase of potentiation 12 . It is now established that incretin/cAMP signaling potentiates GIIS by both protein kinase A-dependent and Epac2A-dependent mechanisms. Epac2A has guanine nucleotide exchange factor activity toward Rap1, a small G protein. Binding of cAMP to Epac2A causes its conformational change, thereby releasing the catalytic region and enabling the binding and the activation of Rap1 13 . A study of Epac2A knockout mice showed that Epac2A is essential in the potentiation of insulin granule exocytosis by cAMP, but primarily in the first phase of potentiation 12 . The following second phase potentiated by cAMP might involve protein kinase A signaling, but the precise mechanism is still unclear. In addition, it has recently been shown that Epac2A is a direct target of some of the antidiabetic sulfonylureas 16, 17 , drugs widely used for treatment of diabetes. Epac2A/Rap1 signaling also is required for augmentation of insulin secretion by a combination of incretin and sulfonylureas 18 . , mouse insulinoma cell lines (beta TC and MIN6) 23, 24 and human pancreatic b-cell lines (betalox5, EndoC-bH1 and EndoC-bH2) [25] [26] [27] . These cell lines often show different insulin secretory profiles from those of native pancreatic b-cells or islets 28 . In fact, many of these cell lines lack incretin responsiveness, and so are unsuitable for investigation of the mechanism of incretin/cAMP signaling. stimulation. These cell lines are useful tools to clarify the mechanism of incretin responsiveness in insulin secretion. As incretin-induced insulin secretion occurs in a glucosedependent manner, the difference in incretin responsiveness between MIN6-K8 and -K20 b-cells might well be due to differences in glucose metabolism of the two cell lines. In fact, metabolome analysis of MIN6-K8 and -K20 b-cells under glucose-stimulated condition showed distinct metabolomic profiles of the two cell lines. In addition, contents of glucose 6-phosphate, fructose 6-phosphate, fructose 1,6-bisphosphate, nicotinamide adenine dinucleotide, glutamate and aspartate are higher in MIN6-K8 b-cells than those in MIN6-K20 b-cells, indicating that both glycolysis and the MA shuttle are enhanced in incretin-responsive MIN6-K8 b-cells in comparison with those in incretin-unresponsive MIN6-K20 b-cells (Figure 1 
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GLUTAMATE PRODUCED THROUGH THE MALATE-ASPARTATE SHUTTLE IS A CRITICAL SIGNAL IN INCRETIN-INDUCED INSULIN SECRETION
Glutamate in b-cells is produced through three metabolic pathways: (i) conversion from a-ketoglutarate by glutamate dehydrogenase 1 in the mitochondria; (ii) conversion from glutamine by glutaminase in the mitochondria; and (iii) transamination of a-ketoglutarate by aspartate aminotransferase 1 associated with the MA shuttle in cytosol. Mitochondrial glutamate was previously proposed as a signal in GIIS [31] [32] [33] , but the notion has been controversial 34, 35 . Metabolic flux analysis is a useful technique to determine isotopomers, as well as altered metabolic rate in the cells. Using stable isotope-labeled [U-¹³C]-glucose, glutamate isotopomers can be measured to learn whether or not the glutamate is produced from glucose. There are six glutamate isotopomers (M [no substitution with ¹³C] and M + 1 to M + 5 [one to five substitutions with ¹³C, respectively]). M and M + 1 isotopomers are the naturally occurring glutamate in cells; M + 2 to M + 5 isotopomers represent glutamate derived from [U-¹³C]-glucose ( Figure 2 ). M + 2 to M + 5 glutamate isotopomers were increased in cytosol, as assessed by metabolic flux analysis, indicating that glutamate is produced from glucose. Inhibition of the MA shuttle by aminooxyacetate, an inhibitor of the MA shuttle 36, 37 , decreased production of M + 2 to M + 5 glutamate isotopomers in cytosol, indicating that cytosolic glutamate is produced through the MA shuttle. In addition, application of glutamate in the presence of cAMP into primary mouse b-cells dose-dependently stimulated exocytosis, as assessed by capacitance measurement. Total internal reflection fluorescence microscopy analysis showed that dimethyl-glutamate, a membranepermeable glutamate precursor that is converted to glutamate by esterase within the cells, amplifies both the first and second phases of glucose-induced insulin granule exocytosis 30 . Together, these findings strongly suggest that cellular glutamate acts as a critical amplifying signal in incretin-induced insulin secretion.
TRANSPORT OF GLUTAMATE INTO INSULIN GRANULES
Glutamate in the cytosol is known to be transported into secretory vesicles through vesicular glutamate transporters (VGLUTs) 38 . VGLUT1 is expressed in mouse pancreatic b-cells, and various mouse and rat b-cell lines; for example, MIN6-K8, bTC6, RIN-m and INS-1E cells 30, 39, 40 . VGLUT2 is expressed in both pancreatic a-cell lines (aTC1-9 cells) and b-cell lines (MIN6-K8, bTC6 and RIN-m cells) 30, 39, 40 . VGLUT3 is also expressed in mouse pancreatic a-and b-cells 40 . Inhibition of glutamate transport into insulin granules by Evans Blue, an inhibitor of glutamate transporters, or knockdown of VGLUT1 did not affect GIIS, but reduced incretin-induced insulin secretion in MIN6-K8 b-cells, suggesting that glutamate transport into insulin granules through VGLUT1 is required for incretin-induced insulin secretion 30 . Glutamate transport through VGLUTs is regulated by electrical potential (D/) and pH gradient (DpΗ) across the vesicular membrane 38 . Glutamate flux into insulin granules is involved in the generation of D/ and DpΗ across the insulin granule membrane 40 . A proton pump, V-ATPase, in insulin granules also contributes to generation of D/ and DpΗ across the insulin granule membrane 41 , a process in which Cl -flux is required 42, 43 . In addition, it was reported that glutamate efflux through excitatory amino acid transporters was involved in the regulation of D/ and DpΗ in . Thus, glutamate flux through insulin granules is regulated by a complex mechanism. Interestingly, impaired glutamate efflux was found to decrease insulin granule exocytosis 40 , further suggesting a critical role of glutamate in insulin secretion. Although the precise mechanism by which glutamate in insulin granules stimulates insulin granule exocytosis remains to be elucidated, total internal reflection fluorescence microscopy analysis showed that dimethyl-glutamate induces exocytosis of insulin granules, suggesting that glutamate in insulin granules might promote recruitment towards and/or fusion of the insulin granules with the plasma membrane (Figure 3) 
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GLUTAMATE PRODUCTION IN PANCREATIC ISLETS OF DIABETIC AND OBESE RAT MODELS
Impaired potentiation of insulin secretion by incretins is found in diabetes in clinical settings 44 . Animal models are useful for studying the pathogenesis and pathophysiology of diabetes. The Goto-Kakizaki rat is a non-obese type 2 diabetes model with defective insulin secretion associated with impaired glucose metabolism in pancreatic b-cells 45 . GIIS is markedly decreased in these rats compared with normal control Wistar rats, but the amplification effect by GLP-1 is somewhat retained. Glucose-stimulated glutamate production was increased slightly, but significantly, in the islets of Goto-Kakizaki rats. In contrast, the Zucker fatty rat, an obesity model as a result of mutation in the leptin receptor gene, shows a higher level of basal insulin secretion and insulin response to glucose. However, these rats showed no potentiation of insulin secretion in response to incretin stimulation. Glucose did not increase glutamate production in the islets of Zucker fatty rats. Dimethyl-glutamate was able to amplify insulin secretion in Zucker fatty rats, mimicking the effect of incretins. Thus, impaired production of 
CONCLUSIONS
A metabolomics-based approach showed that glutamate acts as a key cell signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion. Unresponsiveness to endogenous incretins and unresponsiveness to exogenously administered incretin-related drugs (incretin non-responders) are found among patients with type 2 diabetes; abnormalities in b-cell glutamate signaling might therefore underlie the unresponsiveness to incretins. Clarification of glutamate signaling could contribute to the development of novel therapies, as well as our understanding of the pathophysiology of diabetes and diabetic b-cells. Metabolomics is a powerful approach to unveil metabolic signaling pathways.
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